MaxCyte Q4 Earnings Call Highlights [Yahoo! Finance]
MaxCyte, Inc. (MXCT)
Company Research
Source: Yahoo! Finance
9%), even as its instrument install base grew to 857 and the SeQure Dx acquisition added $1.1 million in revenue. For 2026 management guided total revenue of $30–32 million (core $25–27M, SPL $5M) but warned of near-term headwinds—including an approximately $4 million core revenue impact from select SPL customers and a terminated SPL license—while expecting milestone and royalty contributions (including a recent seven-figure milestone and ~ $2M of expected royalties) to help the outlook. The company launched the ExPERT DTx 96-well electroporation platform in February, targeting earlier-stage discovery with meaningful revenue expected in H2 2026 and into 2027, and said 2025 restructuring cut annual cash burn by $16 million as it exited the year with $155.6 million in cash, equivalents and investments and no debt. Interested in MaxCyte, Inc.? Here are five stocks we like better. MaxCyte: Building the Future of Cell and Gene Therapy Innovation MaxCyte (NASDAQ:MXCT) executives t
Show less
Read more
Impact Snapshot
Event Time:
MXCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MXCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MXCT alerts
High impacting MaxCyte, Inc. news events
Weekly update
A roundup of the hottest topics
MXCT
News
- MaxCyte (MXCT) had its price target lowered by Craig Hallum from $7.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook [Seeking Alpha]Seeking Alpha
- MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- MaxCyte Inc (MXCT) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines Amid Strategic ... [Yahoo! Finance]Yahoo! Finance
- MaxCyte (MXCT) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
MXCT
Earnings
- 3/24/26 - Miss
MXCT
Sec Filings
- 3/27/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- 3/25/26 - Form 10-K
- MXCT's page on the SEC website